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Association of white blood cell 
count with breast cancer burden 
varies according to menopausal 
status, body mass index, and 
hormone receptor status: a case-
control study
Byoungjin park  1, Hye sun Lee  2, Ji Won Lee  1 & seho park3
Breast cancer is a heterogeneous disease that among Korean women has a peak incidence in the 
perimenopausal period. the full epidemiological characteristics of breast cancer in Korean women 
are not yet properly understood. We investigated whether white blood cell (WBC) is related to breast 
cancer burden according to estrogen receptor (eR) and progesterone receptor (pR) status in the context 
of body mass index and menopausal status. We conducted a large case-control study and compared 
WBC counts between patients with breast cancer (N = 4,402) and propensity score-matched controls 
(N = 4,402) selected from the Korean National Health and Nutrition Examination Survey (KNHANES). 
We stratified the study sample by ER/PR status, menopausal status, and body mass index and assessed 
the association between WBC count and breast cancer burden using multinomial logistic regression. 
Compared with controls, non-obese patients with eR+/PR+ breast cancer had significantly higher WBC 
counts regardless of menopausal status (OR 1.293 95% CI 1.139–1.363, p < 0.001 in premenopausal and 
OR 1.049 95% CI 1.019–1.295, p = 0.023 in postmenopausal). there was no relationship between WBC 
count and eR+/PR+ breast cancer among premenopausal obese women. Furthermore, premenopausal 
non-obese women and postmenopausal obese women with eR+/PR+ breast cancer had higher WBC 
counts than those with eR−/PR− breast cancer. Further larger-scale prospective cohort studies are 
warranted to determine these associations in the future.
Breast cancer has by far the highest incidence of all cancer types among women around the world1,2. Contrary to 
the recent drop in the breast cancer incidence in Western countries, the incidence in Korea has been gradually 
rising for more than a decade3,4. The peak incidence of breast cancer in Korea is among women 45–49 years of age, 
whereas that in the USA and Canada is among women 75–79 years of age5,6. Although estrogen exposure, unfa-
vorable lifestyles, and genetic factors are known to be major risk factors for breast cancer, the unique epidemio-
logical features of breast cancer among Korean women are not properly understood. Recently, insulin resistance 
and metabolic syndrome were shown to be associated with an increased risk of breast cancer7–9. However, among 
Korea women, those relationships are limited to only one subtype of breast cancer in postmenopausal women10.
An increasing body of evidence suggests that chronic low-grade inflammation could be linked to the patho-
genesis of some cancers11–13. White blood cell (WBC) count, an inflammatory biomarker, has become a use-
ful predictor of certain diseases as well as a marker of infection14–17. An elevated WBC count, even within the 
normal range, has been associated with cancer incidence and mortality and with atherosclerotic cardiovascular 
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diseases18–20. The role of WBC count as a surrogate for inflammation has not been examined in the context of 
well-known effect modifiers for breast cancer development.
Previous epidemiological studies have demonstrated that obesity, as indicated by body mass index (BMI), 
can influence the breast cancer risk, which can be altered differently according to menopausal status21–23. Several 
studies have attempted to identify the association between WBC counts and breast cancer risk, but no consistent 
evidence has been found, and those studies were not conducted without stratification by menopausal status and 
BMI24,25. Furthermore, hormone receptor positive- and negative- breast tumors are heterogeneous with respect to 
risk factors and etiology26,27. In this regard, we would like to shed light on the interaction between inflammation, 
as indicated by WBC count, and breast cancer burden according to estrogen receptor (ER) and progesterone 
receptor (PR) status in the context of body mass index and menopausal status. We conducted a case-control study 
to investigate whether WBC count is related to breast cancer burden according to ER/PR status in the context of 
body mass index and menopausal status.
Materials and Methods
study population. We selected patients with breast cancer from the breast cancer registry of the Department 
of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, which includes 
anthropometric measures, laboratory data, personal medical history, and clinicopathological features of breast 
cancers. The Institutional Review Board of Yonsei University College of Medicine approved the study. We 
included in the study 4402 female Korean patients who were diagnosed with in situ or invasive carcinoma of 
the breast between November 2005 and December 2012 and subsequently underwent surgery for breast cancer. 
Throughout this period, baseline characteristics of breast cancer patients were similar and sequentially registered 
enough to secure proper stratification by BMI, menopausal status, and hormone receptor status. We excluded 
patients for whom there was no available information about menopause or BMI, those with Stage IV breast can-
cer, and those less than 20 years of age at the time of diagnosis (Fig. 1).
We selected 4402 propensity score-matched controls from the 2010–2012 Korean National Health and 
Nutrition Examination Survey (KNHANES), which was, as a fifth period survey, sampled without duplication 
of participants and performed on well-refined setting, while the earlier KNHANES were sampled again at every 
period due to the possibility of collective and relative duplication of missing data. We used households as the 
sampling units and selected individuals using a stratified, multistage, probability-sampling design according to 
geographic area, sex, and age. We excluded males, individuals with unknown menopause status or BMI, and indi-
viduals with a history of cancer. We assigned each eligible individual a sampling weight indicating the probability 
of being sampled. Therefore, we consider our results to appropriately represent the entire Korean population.
Data collection. We adopted the same variables for analysis from the Severance Hospital registry and the 
KNHANES. Body weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, with the par-
ticipants wearing light indoor clothing without shoes. BMI was calculated as the ratio of weight (kg) to squared 
height (m2). After a 12 h overnight fast, blood samples were obtained through an antecubital vein from the con-
trols. WBC counts were quantified using XE-2100D (Sysmex, Japan). Fasting plasma glucose, total cholesterol, 
Figure 1. Selection of patients and controls for the study.
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triglyceride, HDL-cholesterol, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were 
measured using an automated chemistry analyzer (Hitachi 7600, Tokyo, Japan). Also, an overnight-fasting venous 
blood specimen was collected from all patients within one week after breast cancer diagnosis. WBC counts were 
quantified by an automated blood cell counter (ADVIA 120, NY, USA). Fasting plasma glucose, total choles-
terol, triglyceride, HDL-cholesterol, AST, and ALT were measured using Hitachi 7600–110 Chemistry System 
Autoanalyzer (Hitachi, Tokyo, Japan). Previous study comparing automated blood cell counters has shown that 
there is no difference in reference intervals for WBC counts between two analyzers used in controls and cases, 
respectively28. After definitive surgery for breast cancer, tumor specimens were stained for ER and PR. Specimens 
with more than 1% nuclear-stained cells were defined as positive for ER and/or PR according to the guidelines of 
the American Society of Clinical Oncology-College of American Pathologists29. Menopause status, menarchial 
age, menopausal age, and history of breastfeeding were documented among the patients and the controls by 
a self-administered questionnaire. Menopause was defined as the cessation of menstruation for more than 12 
months or surgical menopausal status in cases and controls.
statistical analysis. We compared the characteristics of the patients and propensity score-matched controls 
using paired t-tests for continuous variables and McNemar’s test for categorical variables. Propensity score was 
created using age, the most well-known confounding variable. We examined potential effects on WBC counts of 
obesity (BMI ≥ 25 kg/m²) and ER/PR status (ER−/PR−, ER+/PR− or ER−/PR+, or ER+/PR+) according to meno-
pausal status. This stratification was based on previous meta-analysis showing the different association between 
body weight and breast cancer risk among ER−/PR−, ER+/PR− or ER−/PR+, or ER+/PR+ by menopausal status27. 
We performed an analysis of covariance (ANCOVA) adjusted for WBC counts of controls to compare differences 
in WBC counts between matched patients and controls among groups in which the patients were ER−/PR−, ER+/
PR− or ER−/PR+, or ER+/PR+. Using multinomial logistic regression, we measured the strength of correlation 
between WBC count (×103 cells/μL) and breast cancer burden according to ER/PR status stratified by BMI and 
menopause after adjusting for continuous variables (age, systolic blood pressure, fasting plasma glucose, total 
cholesterol, triglyceride, HDL-cholesterol, ALT, and age at menarche or age at menopause) and categorical varia-
bles (breastfeeding, hypertension medication, and diabetes medication), including significant variables (p < 0.05) 
in univariate analysis with clinically important variables, while further considering multicollinearity. To test the 
combined effect of menopause status, BMI, and WBC, we tested their interactions with the interaction term for 
menopause status*BMI*WBC by multinomial logistic regression models for outcome. The interaction among 
menopause status, BMI, and WBC was tested at a significance level of 0.2. We conducted all analyses using the 
SAS statistical software, version 9.2 (SAS Institute Inc., Cary, NC, USA). All statistical tests were two-sided, with 
statistical significance determined by p < 0.05.
Results
Table 1 shows the characteristics of the patients and matched controls according to menopausal status. The mean 
age of the premenopausal and postmenopausal women was 42.5 ± 6.1 years and 58.5 ± 7.7 years, respectively. The 
percentage of premenopausal women was 51.8%. Among the premenopausal women, the mean BMI of the con-
trols (22.7 ± 3.1 kg/m2) was higher than that of the patients (22.5 ± 3.1 kg/m2; p < 0.001). There was no significant 
difference in mean BMI between the postmenopausal controls (24.2 ± 3.3 kg/m2) and patients (24.2 ± 3.2 kg/m2). 
Regardless of menopausal status, the patients in each group had higher WBC counts, systolic blood pressure, 
diastolic blood pressure, and fasting plasma glucose than the controls (p < 0.001 for each comparison). HDL cho-
lesterol was lower in the premenopausal patients than in the matched controls, while there was no difference in 
HDL cholesterol between the postmenopausal patients and controls. Regardless of menopausal status, history of 
breastfeeding was more prevalent among the controls, whereas history of medication for hypertension was more 
prevalent among the patients. History of medication for diabetes was more prevalent among the postmenopausal 
patients than among the matched controls, however there was no difference in history of diabetes medication 
between the premenopausal patients and controls.
Premenopausal non-obese women with ER−/PR− or ER+/PR+ breast cancer had higher WBC counts than 
their matched controls (p = 0.010 and p < 0.001, respectively). Postmenopausal women with ER+/PR− or ER−/
PR+ breast cancer exhibited similar trends, but the difference between the patients and controls was not sig-
nificant. In contrast to the patterns in premenopausal non-obese women, premenopausal obese women with 
ER−/PR− breast cancer or ER+/PR− or ER−/PR+ breast cancer did not have higher WBC counts than their 
age-matched controls, and the trend for higher WBC counts relative to those in the controls was weakened in 
those with ER+/PR+ breast cancer (Table 2, Fig. 2a). WBC counts were significantly higher in postmenopausal 
women with ER+/PR+ breast cancer compared with those in matched controls, irrespective of obesity status 
(p < 0.001 and p = 0.014, respectively; Table 3, Fig. 2a).
Figure 2b shows the differences in WBC counts between patients and matched controls by ER/PR status, 
menopause status, and obesity status. ANCOVA showed that the difference in WBC counts between patients 
and matched controls was significantly greater for premenopausal non-obese women with ER+/PR+ breast can-
cer than for those with ER−/PR− breast cancer or ER+/PR− or ER−/PR+ breast cancer (p = 0.020 and p = 0.038, 
respectively). Among postmenopausal women, the difference in WBC counts between patients and controls 
was greater for patients with ER+/PR+ breast cancer than for those with ER−/PR− breast cancer or ER+/PR− or 
ER−/PR+ breast cancer, regardless of whether the women were obese (p = 0.002 and p < 0.001, respectively) or 
non-obese (p = 0.002 and p = 0.009, respectively).
Finally, we assessed the association between WBC count and breast cancer burden according to ER/PR status, 
BMI, and menopausal status. For the analysis, we used multinomial logistic regression analysis after adjustment 
for age, systolic blood pressure, fasting plasma glucose, total cholesterol, triglyceride, HDL cholesterol, alanine 
aminotransferase, the use of hypertension and diabetes medications, history of breastfeeding, menarchial age, 
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and menopausal age (Table 4, Fig. 3). Premenopausal non-obese patients with ER+/PR+ breast cancer had higher 
WBC counts than their age-matched controls [odds ratio (95% CI) = 1.293 (1.139–1.363), p < 0.001]. Likewise, 
postmenopausal non-obese patients with ER+/PR+ breast cancer had higher WBC counts compared to their 
age-matched controls [odds ratio (95% CI) = 1.049 (1.019–1.295), p = 0.023]. Furthermore, premenopausal 
non-obese patients with ER+/PR+ breast cancer had higher WBC counts than premenopausal non-obese patients 
with ER−/PR− breast cancer [odds ratio (95% CI) = 1.203 (1.019–1.420), p = 0.029]. Similarly, postmenopausal 
obese patients with ER+/PR+ breast cancer had higher WBC counts than postmenopausal obese patients with 
ER−/PR− breast cancer [odds ratio (95% CI) = 1.342 (1.023–1.760), p = 0.034]. Menopause*WBC, BMI*WBC, 
and menopause*BMI*WBC were all shown to have significant interactions by multinomial logistic regression 
models for outcome (interaction p value = 0.126, 0.002, and 0.184, respectively).
Discussion
In this case-control study, we found that WBC count was associated differently with breast cancer burden 
depending on menopausal status, BMI, and ER/PR status. Premenopausal non-obese women with ER+/PR+ 
breast cancer had elevated WBC counts compared with both controls and premenopausal non-obese women with 
ER−/PR− breast cancer. Those trends were weaker in premenopausal obese women. Postmenopausal non-obese 
women with ER+/PR+ breast cancer had elevated WBC counts compared with controls, while postmenopausal 
obese women with ER+/PR+ breast cancer had elevated WBC counts compared with postmenopausal obese 
women with ER−/PR− breast cancer.
Emerging evidence suggests that chronic low-grade inflammation plays an important role in cancer develop-
ment. Both menopause and obesity can also play a crucial role in the development of breast cancer30, but their 
interaction may differ according to menopausal status22,31,32. Positive associations between obesity and breast can-
cer risk have been consistently observed in postmenopausal women33–36. However, there is substantial evidence 
that there is an inverse association between obesity and breast cancer risk in premenopausal women37–39. Our 
results showed that WBC count was not associated with breast cancer burden in premenopausal obese women.
WBCs, including neutrophils, monocytes, and eosinophils, produce reactive oxygen species (ROS) and nitric 
oxide species (NOS), which are chemically reactive molecules40. Unless ROS and NOS are properly neutral-
ized by the antioxidant defense system, they can cause damage to cellular proteins, lipids, and DNA that may 
lead to the accumulation of genetic instability, affecting single nucleotide polymorphisms (SNPs) or upregulat-
ing the PI3K-Akt pathway for carcinogenesis41. Large-sample studies that attempted to evaluate the association 
between WBC counts and breast cancer risk without stratification by menopausal status and obesity have pro-
duced inconsistent results24,25. A prospective study demonstrated that leukocyte counts may be a predictor of 
breast cancer, but the study included only postmenopausal women20. Akinbami et al.42 reported that WBC counts 
were higher in patients with breast cancer than in controls, but their study did not include information about 
menopausal status. Okuturlar et al. showed that neutrophil levels were associated with the risk of breast cancer, 
including Stage IV breast cancer43. None of the previous studies included ER/PR status in their analysis. A recent 
meta-analysis assessed the association between the neutrophil-to-lymphocyte ratio as a biomarker using WBC 
subtypes and breast cancer prognosis44. In that study, which was performed in patients with breast cancer without 
control, patients with a higher neutrophil-to-lymphocyte ratio had a higher relapse and a shorter overall sur-
vival. Subgroup analysis showed that studies performed in Eastern countries had perfectly homogeneous results, 
Premenopausal women Postmenopausal women
Controlsa
(N = 2280)
Patients
(N = 2280) p valueb
Controlsa
(N = 2122)
Patients
(N = 2122) p valueb
Age (years) 42.5 (6.1) 42.5 (6.1) 0.999 58.5 (7.7) 58.5 (7.7) 0.999
Body mass index (kg/m²) 22.7 (3.1) 22.5 (3.1) <0.001 24.2 (3.3) 24.2 (3.2) 0.832
Systolic blood pressure (mmHg) 110.6 (14.4) 119.7 (13.3) <0.001 124.1 (18.0) 128.4 (14.9) <0.001
Diastolic blood pressure (mmHg) 72.7 (9.6) 76.7 (9.9) <0.001 76.6 (10.0) 79.0 (9.6) <0.001
Fasting plasma glucose (mg/dL) 92.5 (18.9) 97.3 (15.3) <0.001 98.6 (21.9) 105.4 (25.1) <0.001
Total cholesterol (mg/dL) 186.1 (32.7) 179.6 (31.8) <0.001 204.0 (36.4) 197.0 (35.7) <0.001
Triglyceride (mg/dL) 99.2 (81.4) 98.3 (67.1) 0.726 133.1 (80.8) 127.8 (71.0) 0.044
HDL cholesterol (mg/dL) 57.1 (12.5) 55.4 (12.0) <0.001 54.2 (13.1) 53.1 (12.0) 0.020
White blood cells (×103 cells/μL) 5.6 (1.6) 6.0 (1.7) <0.001 5.7 (1.6) 5.9 (1.6) <0.001
Aspartate aminotransferase (IU) 18.5 (6.8) 18.9 (15.9) 0.356 23.1 (10.0) 22.9 (16.1) 0.748
Alanine aminotransferase (IU) 15.7 (11.2) 17.8 (24.6) 0.011 21.2 (17.0) 22.4 (16.3) 0.118
Age at menarche (years) 14.2 (1.7) 14.3 (1.5) 0.052 15.8 (2.0) 15.7 (1.9) 0.185
Age at menopause (years) 49.0 (4.8) 49.4 (5.4) 0.002
Breastfeeding (%) 68.5 50.9 <0.001 86.9 74.4 <0.001
Hypertension medication (%) 4.1 6.2 <0.001 30.8 37.6 <0.001
Diabetes medication (%) 1.4 1.5 0.700 8.6 13.2 <0.001
Table 1. Characteristics of breast cancer patients and age-matched controls according to menopausal status. 
Data are expressed as the mean (standard deviation) for continuous variables or as the percentage for categorical 
variables. aControls are propensity score-matched data. bp values calculated using paired t-test or McNemar’s test.
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whereas Western countries did not. A distinguishing feature of our study is that it attempts to elucidate a role of 
the interaction between WBC count and ER/PR status in the context of menopause and BMI.
The prevalence of obesity among Korean women has gradually decreased since 200145, but the incidence of 
breast cancer has increased over the last decade4. The age-frequency distribution of breast cancer among Korean 
women is unimodal, with peak incidence at 45–49 years of age5. Dense breast on mammography, a potent risk 
factor for breast cancer, is more prevalent among Korean women, especially before menopause, than among 
women from Western countries46. Those distinctive epidemiological features warrant more investigation of the 
interplay between well-known risk factors such as obesity and menopause and the emerging role of inflammation 
in cancer development.
Non-obese
Controlsa
(N = 385)
ER−/PR−
(N = 385) p valueb
Controlsa
(N = 297)
ER+/PR− or
ER−/PR+
(N = 297) P valueb
Controlsa
(N = 1185)
ER+/PR+
(N = 1185) p valueb
Age (years) 40.7 (6.7) 40.7 (6.7) 0.999 42.2 (6.4) 42.2 (6.4) 0.999 42.5 (5.8) 42.5 (5.8) 0.999
Body mass index (kg/m²) 21.3 (2.0) 21.5 (1.9) 0.123 21.8 (1.9) 21.7 (2.0) 0.668 21.7 (1.9) 21.3 (1.9) <0.001
Systolic blood pressure 
(mmHg) 106.4 (12.2) 116.3 (11.8) <0.001 108.7 (12.8) 117.7 (12.3) <0.001 109.5 (13.5) 119.3 (13.2) <0.001
Diastolic blood pressure 
(mmHg) 70.0 (8.4) 74.1 (9.2) <0.001 71.5 (8.9) 76.0 (10.4) <0.001 72.1 (9.5) 76.4 (9.5) <0.001
Fasting plasma glucose 
(mg/dL) 90.4 (10.7) 96.8 (13.8) <0.001 89.2 (8.3) 97.5 (16.7) <0.001 91.3 (18.3) 95.8 (12.4) <0.001
Total cholesterol (mg/dL) 181.4 (30.4) 175.3 (31.2) 0.028 182.7 (33.0) 179.4 (31.6) 0.427 186.0 (31.3) 178.3 (30.8) <0.001
Triglyceride (mg/dL) 86.6 (42.6) 99.2 (70.1) 0.011 92.9 (47.9) 97.3 (75.2) 0.454 91.1 (56.1) 89.2 (54.8) 0.493
HDL cholesterol (mg/dL) 59.8 (12.8) 55.3 (12.4) <0.001 58.1 (13.0) 55.3 (11.8) 0.015 57.7 (12.1) 56.9 (12.1) 0.238
White blood cells (×103 
cell/μL) 5.5 (1.4) 5.8 (1.7) 0.010 5.6 (1.5) 5.8 (1.7) 0.053 5.5 (1.6) 6.0 (1.7) <0.001
Aspartate 
aminotransferase (IU) 17.5 (5.3) 20.4 (32.6) 0.210 18.0 (4.6) 18.4 (5.7) 0.558 18.1 (6.2) 18.1 (6.7) 0.970
Alanine 
aminotransferase (IU) 13.8 (9.6) 19.7 (50.4) 0.104 14.5 (6.2) 17.3 (10.3) 0.017 14.8 (10.5) 15.9 (10.2) 0.073
Age at menarche (years) 14.1 (1.7) 14.1 (1.6) 0.486 14.2 (1.6) 14.4 (1.6) 0.283 14.2 (1.7) 14.3 (1.5) 0.057
Breastfeeding (%) 65.1 45.9 <0.001 70.4 56.5 <0.001 67.8 48.7 <0.001
Hypertension 
medication (%) 1.6 3.4 0.089 5.1 5.1 0.999 2.8 5.3 0.001
Diabetes medication (%) 1.0 0.5 0.414 0.3 3.4 0.006 0.7 0.9 0.637
Obese Controls
a
(N = 92)
ER−/PR−
(N = 92) p value
b Controlsa
(N = 69)
ER+/PR− or
ER−/PR+
(N = 69)
P valueb Controls
a
(N = 252)
ER+/PR+
(N = 252) p value
b
Age (years) 42.1 (6.4) 42.1 (6.4) 0.999 43.8 (6.4) 43.8 (6.4) 0.999 44.9 (5.2) 44.9 (5.1) 0.999
Body mass index (kg/m²) 27.3 (1.9) 27.2 (2.1) 0.568 28.0 (2.5) 27.9 (3.1) 0.879 27.7 (2.5) 27.5 (2.9) 0.298
Systolic blood pressure 
(mmHg) 118.8 (18.3) 124.5 (12.8) 0.019 118.8 (15.1) 123.7 (13.7) 0.013 119.4 (16.1) 126.7 (13.9) <0.001
Diastolic blood pressure 
(mmHg) 77.4 (10.1) 81.3 (10.7) 0.006 76.8 (9.8) 78.5 (9.4) 0.227 78.3 (10.0) 81.4 (9.5) <0.001
Fasting plasma glucose 
(mg/dL) 102.9 (38.6) 98.9 (18.9) 0.517 105.0 (38.4) 103.6 (17.6) 0.881 99.4 (21.1) 104.1 (23.5) 0.101
Total cholesterol (mg/dL) 199.6 (50.5) 186.1 (38.8) 0.158 189.0 (36.3) 188.9 (42.4) 0.992 192.2 (33.4) 189.6 (31.3) 0.558
Triglyceride (mg/dL) 158.6 (279.0) 129.8 (133.5) 0.452 135.5 (108.2) 127.9 (64.3) 0.655 128.1 (67.3) 117.0 (55.6) 0.095
HDL cholesterol (mg/dL) 52.5 (12.2) 50.6 (9.8) 0.369 49.8 (12.6) 50.6 (11.6) 0.714 53.0 (10.8) 52.2 (11.1) 0.526
White blood cells (×103 
cell/μL) 6.4 (1.7) 6.0 (19) 0.108 6.1 (2.0) 6.0 (1.7) 0.731 6.1 (1.8) 6.3 (2.0) 0.201
Aspartate 
aminotransferase (IU) 19.8 (6.7) 20.7 (8.5) 0.548 24.5 (20.6) 22.4 (11.4) 0.672 21.0 (7.8) 20.0 (13.4) 0.473
Alanine 
aminotransferase (IU) 20.4 (12.2) 21.4 (15.6) 0.750 21.5 (20.5) 24.4 (12.9) 0.558 22.1 (15.1) 22.1 (20.2) 0.994
Age at menarche (years) 14.2 (1.7) 14.0 (1.7) 0.281 14.0 (1.6) 14.3 (1.6) 0.189 14.4 (1.9) 14.4 (1.6) 0.928
Breastfeeding (%) 71.1 57.8 0.064 72.1 60.3 0.144 72.8 57.6 <0.001
Hypertension 
medication (%) 10.9 9.8 0.818 2.9 11.6 0.033 10.7 13.1 0.386
Diabetes medication (%) 5.4 3.3 0.414 4.5 1.5 0.317 4.0 3.2 0.617
Table 2. Characteristics of premenopausal patients with breast cancer and age-matched controls according to 
obesity and ER/PR status. Data are expressed as the mean (standard deviation) for continuous variables or the 
percentage for categorical variables. Non-obese and obese were defined as body mass index <25 kg/m² and 
≥25 kg/m², respectively. aControls are propensity score-matched data. bp values calculated using paired t-test or 
McNemar’s test.
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While metabolic syndrome and insulin resistance, as inflammatory conditions, have been noticed to be asso-
ciated with breast cancer development and subsequent progression7–9, there are controversies, regarding discrep-
ancies according to menopause21–23, as well as some limitations in Korean women. One Korean cohort study in 
which 23,830 Korean women 50–64 years of age were examined reported that metabolic syndrome was related 
to the risk of breast cancer after adjustment for age and BMI47. That study did not account for menopausal status, 
although most of the participants were likely postmenopausal, nor did it consider different breast cancer sub-
types. A recent epidemiological study of postmenopausal Korean women showed that insulin resistance was inde-
pendently associated only with luminal B subtype breast cancer10, which is included in the ER+/PR+ phenotype48.
ER and PR are found in about two-thirds of breast cancers, representing favorable therapeutic and prognostic 
factors. In terms of breast cancer pathogenesis, the risk of breast cancer development associated with weight gain, 
a surrogate for increasing subclinical inflammation, has been shown to be higher for ER+/PR+ breast cancer than 
for ER−/PR− breast cancer27. Approximately 40% of ER+ breast cancers fail to respond to hormone therapy49. ER 
and PR status can be a precipitating factor in breast cancer development through its interplay with inflammation, 
which may also influence endocrine resistance. Pro-inflammatory cytokines, such as tumor necrosis factor-α 
(TNF-α), increase the transcriptional activity of the NF-κB and JNK pathways and may subsequently induce 
tumorigenesis or resistance to hormone therapy50. In a case-case analysis of epidemiological risk factors for breast 
Figure 2. Comparison of WBC counts between patients and matched controls (ER−/PR−, ER+/PR− or ER−/
PR+, ER+/PR+) according to menopause status and obesity status. *P < 0.05, calculated by paired t-test (a). 
Differences in WBC counts between patients and matched controls according to menopause status and obesity 
status. *Difference between ER−/PR− vs. ER+/PR− or ER−/PR+ and ER+/PR+, P < 0.05, calculated by ANCOVA 
(adjusted WBC counts of controls). †Difference between ER+/PR− or ER−/PR+ vs. ER−/PR− and ER+/PR+, 
P < 0.05, calculated by ANCOVA (adjusted WBC counts of controls) (b).
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cancer, women less than 50 years of age with ER−/PR− tumors were more likely to be obese than those with ER+/
PR+ tumors51. Obesity per se has been mainly associated with postmenopausal ER+/PR+ breast cancer27. Our 
study reported that menopausal status, BMI, and WBC showed a significant interaction by multinomial logistic 
regression models. Considering how previous studies have shown that obesity can be associated differently with 
breast cancer status, our findings suggest that among non-obese women, WBC may be related to breast cancer 
burden. Among Korean women, breast cancer has peak incidence in the perimenopausal period, with the number 
of obese women being lower than that of non-obese women10,52.
Our study has a few limitations. First, because our study was a case-control study, the exact cause-effect 
relationship between WBC count and ER/PR status according to obesity status and menopausal status remains 
Non-obese
Controlsa
(N = 422)
ER−/PR−
(N = 422) p valueb
Controlsa
(N = 11)
ER+/PR− or
ER−/PR+
(N = 411) P valueb
Controlsa
(N = 522)
ER+/PR+
(N = 522) p valueb
Age (years) 57.2 (6.7) 57.2 (6.7) 0.999 58.5 (7.3) 58.5 (7.3) 0.999 57.7 (8.0) 57.7 (8.0) 0.999
Body mass index (kg/m²) 22.2 (1.9) 22.2 (1.6) 0.846 22.3 (1.8) 22.3 (1.7) 0.623 22.3 (1.7) 22.4 (1.7) 0.282
Systolic blood pressure 
(mmHg) 120.7 (18.7) 126.1 (14.7) <0.001 124.0 (19.0) 126.9 (15.2) 0.013 121.6 (17.6) 128.2 (15.0) <0.001
Diastolic blood pressure 
(mmHg) 75.7 (9.9) 78.4 (9.4) <0.001 76.4 (10.2) 77.0 (9.4) 0.324 75.1 (10.0) 79.2 (9.7) <0.001
Fasting plasma glucose (mg/
dL) 98.4 (22.1) 103.5 (21.7) 0.019 95.2 (12.3) 103.5 (23.6) <0.001 95.2 (19.6) 103.3 (24.4) <0.001
Total cholesterol (mg/dL) 202.2 (35.7) 195.2 (37.4) 0.047 200.8 (31.7) 197.8 (31.8) 0.442 200.8 (34.3) 196.6 (37.3) 0.2211
Triglyceride (mg/dL) 122.9 (76.4) 119.2 (64.6) 0.510 121.0 (77.1) 116.3 (66.5) 0.396 118.6 (74.5) 122.2 (73.3) 0.5169
HDL-cholesterol (mg/dL) 55.1 (13.6) 54.7 (12.6) 0.651 56.4 (13.6) 54.5 (12.9) 0.074 56.0 (12.8) 55.1 (11.9) 0.312
White blood cells (×103 cell/
μL) 5.5 (1.5) 5.6 (1.4) 0.526 5.5 (1.7) 5.6 (1.6) 0.822 5.5 (1.4) 5.9 (1.5) <0.001
Aspartate aminotransferase 
(IU) 23.3 (12.0) 21.6 (10.0) 0.131 22.2 (5.6) 23.9 (23.1) 0.429 22.0 (6.8) 23.4 (21.5) 0.330
Alanine aminotransferase (IU) 21.8 (23.2) 20.6 (13.1) 0.523 18.2 (6.8) 20.7 (12.9) 0.046 18.3 (10.2) 22.0 (21.5) 0.019
Age at menarche (years) 15.7 (1.9) 15.8 (1.8) 0.512 15.6 (2.0) 15.7 (2.0) 0.909 15.8 (2.0) 15.6 (2.0) 0.195
Age at menopause (years) 49.0 (4.6) 49.4 (5.1) 0.148 49.3 (4.5) 50.0 (4.9) 0.088 48.4 (5.0) 48.5 (6.2) 0.608
Breastfeeding (%) 82.6 73.8 0.002 87.0 69.9 <0.0001 86.1 70.1 <0.001
Hypertension medication (%) 22.0 28.0 0.030 25.3 27.5 0.469 21.8 30.3 <0.001
Diabetes medication (%) 6.2 10.0 0.029 5.6 10.7 0.009 7.3 10.6 0.058
Obese Controls
a
(N = 228)
ER−/PR−
(N = 228) p value
b Controlsa
(N = 193)
ER+/PR− or
ER−/PR+
(N = 193)
P valueb Controls
a
(N = 346)
ER+/PR+
(N = 346) p value
b
Age (years) 59.5 (7.6) 59.5 (7.6) 0.999 59.5 (7.4) 59.5 (7.4) 0.999 60.4 (8.2) 60.4 (8.2) 0.999
Body mass index (kg/m²) 27.6 (2.3) 27.4 (2.1) 0.500 27.6 (2.7) 27.3 (2.1) 0.174 27.5 (2.7) 27.7 (2.5) 0.237
Systolic blood pressure 
(mmHg) 127.8 (16.5) 129.0 (14.2) 0.374 127.3 (15.8) 130.3 (14.4) 0.045 127.8 (17.2) 131.8 (14.8) <0.001
Diastolic blood pressure 
(mmHg) 78.3 (9.5) 80.2 (8.7) 0.041 78.7 (9.2) 80.0 (9.8) 0.176 78.2 (10.0) 80.5 (10.0) 0.002
Fasting plasma glucose (mg/
dL) 103.4 (25.1) 109.0 (27.4) 0.114 104.2 (24.6) 108.1 (30.6) 0.463 101.5 (26.2) 109.2 (26.7) 0.014
Total cholesterol (mg/dL) 203.9 (40.5) 196.2 (34.0) 0.146 215.5 (37.7) 196.7 (35.3) 0.002 209.4 (39.3) 200.2 (35.3) 0.041
Triglyceride (mg/dL) 160.2 (87.0) 143.0 (62.6) 0.044 161.8 (88.4) 129.9 (60.2) <0.001 149.0 (79.8) 152.6 (85.3) 0.641
HDL-cholesterol (mg/dL) 51.2 (12.2) 49.8 (10.6) 0.294 51.6 (12.0) 51.5 (11.2) 0.956 50.4 (12.0) 49.2 (9.6) 0.247
White blood cells (×103 cell/
μL) 5.9 (1.5) 5.9 (1.6) 0.867 5.9 (1.5) 5.9 (1.5) 0.953 6.0 (1.6) 6.3 (1.6) 0.014
Aspartate aminotransferase 
(IU) 25.3 (15.7) 23.3 (9.3) 0.239 23.9 (8.2) 21.0 (7.0) 0.026 23.5 (9.2) 23.5 (10.8) 0.974
Alanine aminotransferase (IU) 23.7 (15.8) 24.3 (14.3) 0.740 25.0 (13.7) 21.4 (11.6) 0.064 24.1 (22.4) 25.8 (15.3) 0.399
Age at menarche (years) 16.1 (2.1) 16.0 (1.9) 0.702 16.1 (2.3) 15.7 (2.0) 0.056 15.8 (2.0) 15.7 (1.8) 0.478
Age at menopause (years) 49.1 (4.8) 50.3 (5.0) 0.006 49.7 (4.4) 50.2 (4.4) 0.281 49.1 (5.3) 49.3 (5.5) 0.686
Breastfeeding (%) 90.8 83.7 0.020 91.7 80.7 0.002 88.1 77.3 <0.001
Hypertension medication (%) 46.5 57.0 0.016 42.5 45.6 0.527 44.8 55.2 0.0058
Diabetes medication (%) 12.7 16.2 0.276 16.1 18.1 0.586 10.1 19.1 0.001
Table 3. Characteristics of postmenopausal patients with breast cancer and age-matched controls according 
to obesity and ER/PR status. Data are expressed as the mean (standard deviation) for continuous variables or 
the percentage for categorical variables. Non-obese group and obese were defined as body mass index<25 kg/
m² and ≥25 kg/m², respectively. aControls are propensity score-matched data. bp values calculated using paired 
t-test or McNemar’s test.
8Scientific RepoRts |          (2019) 9:5762  | https://doi.org/10.1038/s41598-019-42234-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
unclear. Although it is plausible that WBC may reflect underlying inflammation and, in turn, affect breast cancer 
risk, higher WBC counts may result from the stress that comes after receiving a cancer diagnosis. Also, WBC 
counts in controls and cases were measured separately in different laboratories, with very high concordance of 
general blood cell counts among various automated hematology analyzers53,54, which may have led to differ-
ential misclassification of laboratory errors. Prospective longitudinal studies are needed to verify the effects of 
those interactions on the development of breast cancer, especially in Asian women. Second, some inflammatory 
Premenopause, BMI < 25 kg/m² Premenopause, BMI ≥ 25 kg/m²
OR (95% CI) p valuea OR (95% CI) p valuea
Cases (ER−/PR−) vs. Controls 1.075 (0.921–1.255) 0.358 1.170 (0.924–1.482) 0.193
Cases (ER−/PR+ or ER+/PR−) vs. Controls 1.279 (1.061–1.541) 0.009 1.242 (0.817–1.890) 0.310
Cases (ER+/PR+) vs. Controls 1.293 (1.185–1.411) <0.001 1.082 (0.915–1.279) 0.356
Cases (ER−/PR+ or ER+/PR−) vs. Cases (ER−/PR−) 1.190 (0.941–1.504) 0.146 1.062 (0.663–1.700) 0.802
Cases (ER+/PR+) vs. Cases (ER−/PR−) 1.203 (1.019–1.42) 0.028 0.925 (0.704–1.214) 0.573
Cases (ER−/PR+ or ER+/PR−) vs. Cases (ER−/PR−) 1.011 (0.834–1.226) 0.910 0.871 (0.562–1.349) 0.535
Postmenopause, BMI < 25 kg/
m²
Postmenopause, BMI ≥ 25 kg/
m²
OR (95% CI) p valueb OR (95% CI) p valueb
Cases (ER−/PR−) vs. Controls 0.966 (0.830–1.124) 0.653 0.820 (0.652–1.032) 0.091
Cases (ER−/PR+ or ER+/PR−) vs. Controls 1.010 (0.849–1.201) 0.912 1.020 (0.821–1.269) 0.855
Cases (ER+/PR+) vs. Controls 1.149 (1.019–1.295) 0.023 1.101 (0.936–1.294) 0.245
Cases (ER−/PR+ or ER+/PR−) vs. Cases (ER−/PR−) 1.045 (0.838–1.304) 0.694 1.244 (0.914–1.693) 0.165
Cases (ER+/PR+) vs. Cases (ER−/PR−) 1.189 (0.989–1.430) 0.064 1.342 (1.023–1.760) 0.033
Cases (ER−/PR+ or ER+/PR−) vs. Cases (ER−/PR−) 1.138 (0.930–1.392) 0.210 1.079 (0.830–1.403) 0.571
Table 4. Multinomial logistic regression analysis showing the strength of correlation between WBC count and 
breast cancer status. aPremenopausal model: Adjusted for age, systolic blood pressure, fasting plasma glucose, 
total cholesterol, triglyceride, HDL-cholesterol, ALT, age at menarche, breastfeeding, hypertension medication, 
and diabetes medication. bPostmenopausal model: Adjusted for age, systolic blood pressure, fasting plasma 
glucose, total cholesterol, triglyceride, HDL-cholesterol, ALT, age at menopause, breastfeeding, hypertension 
medication, and diabetes medication.
Figure 3. Forest plot. Models of premenopausal women were adjusted for age, systolic blood pressure, fasting 
plasma glucose, total cholesterol, triglyceride, HDL cholesterol, alanine aminotransferase, age at menarche, 
breastfeeding, hypertension medication, and diabetes medication. Models of postmenopausal women were 
adjusted for age, systolic blood pressure, fasting plasma glucose, total cholesterol, triglyceride, HDL cholesterol, 
alanine aminotransferase, age at menopause, breastfeeding, hypertension medication, and diabetes medication. 
*Difference between control and ER−/PR−, ER+/PR− or ER−/PR+, or ER+/PR+; P < 0.05, calculated by 
multinomial logistic regression analysis. †Difference between ER−/PR− and ER+/PR− or ER−/PR+, or ER+/PR+; 
P < 0.05, calculated by multinomial logistic regression.
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markers such as C-reactive protein, interleukin-6, serum amyloid-A, and prostaglandin E2 were not measured at 
the beginning of the study. Those markers can be indicators of chronic low-grade inflammation but have not been 
taken into consideration when relating breast cancer to the presence of obesity. Third, cases were selected from 
hospital registry between 2005 and 2012, but controls were selected between 2010 and 2012 from KNHANES, 
albeit for proper stratification in cases and for excluding duplication of participants and minimizing missing data 
in controls.
In conclusion, compared with those in controls, WBC counts were significantly elevated in non-obese patients 
with ER+/PR+ breast cancer, irrespective of menopause. Further larger-scale prospective cohort studies are war-
ranted to determine these associations in the future.
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